Market Overview

Investigation Report on Chinese Insulin Glargine Market, 2018-2022 - ResearchAndMarkets.com

Share:

The "Investigation
Report on Chinese Insulin Glargine Market, 2018-2022"
report
has been added to ResearchAndMarkets.com's offering.

Insulin Glargine is the first long-acting insulin produced by simulating
recombinant DNA technology. It was approved to be put into use by FDA in
Apr. 2000 and then by the European Agency for the Evaluation of
Medicinal Products (EMEA) in Jun. 2000. The sales value has been growing
since Insulin Glargine entered China and exceeded CNY 800 million in
2017.

In China, the third generation of insulin is still under promotion. Due
to the relatively high price, it has not yet dominated the market. The
second and third generations of insulin will form a market pattern of
dislocation competition.

At present, the Chinese market is dominated by Aventis Behring's
brand-name drug and the generic drugs of Gan & Lee Pharmaceuticals and
Zhuhai United Laboratories Co., Ltd. However, it is expected that the
market pattern in China will change in the next few years as some
domestic enterprises are speeding up the development of generic Lantus.

According to the researcher, the incidence of diabetes keeps increasing
in China with the improvement of people's living standard and the change
of lifestyle, which expands the diabetes drug market year by year. The
market size of diabetes drugs in China exceeded CNY 30 billion in 2017.
The third-generation insulin products have been technically improved,
reduced some shortcomings of the second-generation products, and
effectively shortened the treatment time. They are expected to
completely replace the second-generation insulin in the future. It is
foreseeable that Insulin Glargine is the product with most growth
potential among the three generations of insulin products in China, and
its market size will continue to grow from 2018 to 2022.

Key Topics Covered:

1 Relevant Concepts of Insulin Glargine

2 Sales of Insulin Glargine in China, 2013-2017

3 Analysis on Major Insulin Glargine Manufacturers in China, 2013-2017

4 Prices of Different Manufacturers' Insulin Glargine in China, 2017-2018

5 Prospect of Chinese Insulin Glargine Market, 2018-2022

Companies Mentioned

  • Aventis Behring
  • Gan & Lee Pharmaceuticals
  • Zhuhai United Laboratories Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/h5zpmn/investigation?w=4

View Comments and Join the Discussion!